e-learning
resources
Paris 2018
Monday, 17.09.2018
COPD: from LABA/ICS to LABA/LAMA/ICS
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Late Breaking Abstract - Extrafine single inhaler triple therapy improves quality of life in COPD. Analysis of SGRQ subdomains of the TRIBUTE Study
L. Fabbri (Ferrara, Italy), D. Singh (Manchester, United Kingdom), I. Valente (Parma, Italy), A. Guasconi (Parma, Italy), H. Prunier (Parma, Italy), G. Georges (Cary, United States of America), A. Papi (Ferrara, Italy)
Source:
International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS
Session:
COPD: from LABA/ICS to LABA/LAMA/ICS
Session type:
Oral Presentation
Number:
2131
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Fabbri (Ferrara, Italy), D. Singh (Manchester, United Kingdom), I. Valente (Parma, Italy), A. Guasconi (Parma, Italy), H. Prunier (Parma, Italy), G. Georges (Cary, United States of America), A. Papi (Ferrara, Italy). Late Breaking Abstract - Extrafine single inhaler triple therapy improves quality of life in COPD. Analysis of SGRQ subdomains of the TRIBUTE Study. 2131
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
ERS clinical practice guidelines on treatment of sarcoidosis
Related content which might interest you:
Single inhaler triple therapy in patients with COPD: response rates in health-related quality of life in the IMPACT Trial
Source: International Congress 2018 – Clinical trials in COPD: new results
Year: 2018
Late Breaking Abstract - Extrafine triple therapy reduces exacerbations in GOLD B COPD patients: post-hoc analysis of TRILOGY and TRINITY
Source: International Congress 2017 – Update and new perspectives in Airway Diseases
Year: 2017
Late Breaking Abstract - Assessment of physical functioning and handling with Tiotropium/Olodaterol (T/O) in patients with COPD requiring long-acting dual bronchodilation in an Italian cohort of patients.
Source: International Congress 2019 – COPD treatment: cohorts and real-world studies
Year: 2019
Late Breaking Abstract - Reduction of COPD exacerbations with extrafine single inhaler triple therapy: post-hoc analysis by exacerbation treatment of the TRIBUTE study
Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS
Year: 2018
Late Breaking Abstract - Impact of ICS/LABA and LABA/LAMA FDCs on lung function and exacerbation of COPD: a network meta-analysis
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018
Single inhaler triple therapy in patients with COPD: patient-reported dyspnoea and health status from the IMPACT Trial
Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet?
Year: 2018
TriOptimize VII: Improvement of health-related quality of life after 3 months treatmentwith extrafine single inhaler triple therapy in COPD patients in a real-world setting.
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020
Late Breaking Abstract - Real-world evidence of dual bronchodilator therapy using Clinical COPD Questionnaire in 4700 COPD patients
Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD
Year: 2020
Late Breaking Abstract - Factors associated with health-status of COPD patients on Dry Powder Inhaler (DPI) maintenance therapy
Source: Virtual Congress 2021 – Highlights for primary care in 2021
Year: 2021
Late Breaking Abstract - Impact of eosinophil levels on lung function and exacerbation benefits with co-suspension delivery technology budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) in COPD (KRONOS study subgroup analysis)
Source: International Congress 2018 – Integrated care and non-pharmacological management of COPD
Year: 2018
Late Breaking Abstract - A connected inhaler system improves adherence to fluticasone furoate/vilanterol in asthma
Source: International Congress 2019 – Blood eosinophils and more in airway diseases
Year: 2019
Late Breaking Abstract - IMPACT study — single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: healthcare resource utilization and costs — UK
Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS
Year: 2018
LATE-BREAKING ABSTRACT: Cost-effectiveness of the LABA/LAMA dual bronchodilator QVA149 in a Swedish setting
Source: Annual Congress 2013 –Health economics of airway diseases
Year: 2013
Late Breaking Abstract - A randomized clinical study to assess the impact of budesonide/formoterol (BUD/FM) pMDI medication reminders on adherence in COPD patients
Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet?
Year: 2018
A prospective observational study of the impact of COPD on daily life following the initiation of indacaterol
Source: International Congress 2014 – Clinical assessment of airway diseases
Year: 2014
Late Breaking Abstract - Cost effectiveness of as-needed budesonide/formoterol vs low-dose ICS maintenance therapy in mild asthma patients: A UK perspective
Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness
Year: 2019
Late Breaking Abstract - COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS
Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD
Year: 2020
Tiotropium + olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life versus placebo
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Late Breaking Abstract - Compare outcomes between COPD patients treated with Tiotropium/Olodaterol (TIO/OLO) and other fixed-dose LAMA/LABAs
Source: Virtual Congress 2020 – COPD and the impact of comorbidities
Year: 2020
Late Breaking Abstract - Impact of COPD symptom-related attacks on quality of life and exacerbations
Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept